Ac-GLAR-OH

Ref. 3D-PP48045

Informations sur le produit

• Nom: Ac-GLAR-OH

Description

Peptide Ac-GLAR-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Ac-GLAR-OH include the following: Preparation and Identification of Peptides with alpha-Glucosidase Inhibitory Activity from Shiitake Mushroom (Lentinus edodes) Protein Y Zhang, Y Chen, X Liu, W Wang, J Wang, X Li, S Sun - Foods, 2023 - mdpi.comhttps://www.mdpi.com/2304-8158/12/13/2534 Rapid screening of the novel bioactive peptides with notable alpha-glucosidase inhibitory activity by UF-LC-MS/MS combined with three-AI-tool from black beans Y Li, X Wang, X Guo, L Wei, H Cui, Q Wei, J Cai - International Journal of , 2024 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0141813024017872 Achieving Composite Endpoint of A1C< 7.0% without Weight Gain or Hypoglycemia with Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes-Post X XIAO, C WANG, F WANG, P LI, L GU - Diabetes, 2018 - Am Diabetes Assochttps://diabetesjournals.org/diabetes/article/67/Supplement_1/1069-P/53775 The active site of human C4a anaphylatoxin TE Hugli, MS Kawahara, CG Unson - Molecular , 1983 - Elsevierhttps://www.sciencedirect.com/science/article/pii/0161589083900081 Biochemistry and biology of anaphylatoxins TE Hugli - Complement, 1986 - karger.comhttps://karger.com/cod/article-abstract/3/3/111/69891 GlaR (YugA)-a novel RpiR-family transcription activator of the Leloir pathway of galactose utilization in Lactococcus lactis IL1403 T Aleksandrzak-Piekarczyk , K Szatraj - , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/mbo3.714 Effect of three intensive insulin treatments on newly diagnosed type 2 diabetes in different insulin resistant status S Zheng, X LI, Q LI - Clinical Medicine of China, 2010 - pesquisa.bvsalud.orghttps://pesquisa.bvsalud.org/portal/resource/pt/wpr-389451 Exploration of the nutritional and functional properties of underutilized grains as an alternative source for the research of food-derived bioactive peptides S Fernandez-Tome , TJ Ashaolu - Nutrients, 2023 - mdpi.comhttps://www.mdpi.com/2072-6643/15/2/351 Optimization, identification, and comparison of peptides from germinated chickpea (Cicer arietinum) protein hydrolysates using either papain or ficin and their S Chandrasekaran , EG de Mejia - Food chemistry, 2022 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0308814621027230 The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes R Retnakaran, J Pu, C Ye, A Emery, CK Kramer - Cardiovascular , 2023 - Springerhttps://link.springer.com/article/10.1186/s12933-023-01781-z The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial R Retnakaran, C Ye, A Emery, CK Kramer - Nature , 2022 - nature.comhttps://www.nature.com/articles/s41467-022-33867-9 Combining basal insulin analogs with glucagon-like peptide-1 mimetics R Perfetti - Diabetes Technology & Therapeutics, 2011 - liebertpub.comhttps://www.liebertpub.com/doi/abs/10.1089/dia.2010.0250 Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy P Hollander, D Sugimoto, A Vlajnic, C Kilo - Journal of diabetes and its , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1056872715002251 Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens NP Murphy, SM Keane, KK Ong , M Ford-Adams - Diabetes , 2003 - Am Diabetes Assochttps://diabetesjournals.org/care/article-abstract/26/3/799/29282 Nutritional composition, health benefits and bio-active compounds of chickpea (Cicer arietinum L.) N Begum, QU Khan , LG Liu, W Li, D Liu - Frontiers in Nutrition, 2023 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580981/ The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus MP Baruah, S Kalra - on Endocrine, Metabolic & Immune Drug , 2012 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/emi/2012/00000006/00000002/art00005 Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system MC Moore, MS Smith, MK Turney - Diabetes, Obesity , 2011 - Wiley Online Libraryhttps://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1463-1326.2011.01418.x Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes MC Bunck , A Corner, B Eliasson, RJ Heine - Diabetes , 2011 - Am Diabetes Assochttps://diabetesjournals.org/care/article-abstract/34/9/2041/38690 Comparative efficacy and safety of basal insulins: A review H Vargas-Uricoechea, P Aschner - Diabetes & Metabolic Syndrome , 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1871402121003386 Exenatide improves beta-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial DH van Raalte, MC Bunck , MM Smits - European journal of , 2016 - academic.oup.comhttps://academic.oup.com/ejendo/article-abstract/175/4/345/6654912 Effect of 3 years of treatment with exenatide on postprandial glucagon levels DH van Raalte - Diabetes Care, 2016 - academia.eduhttps://www.academia.edu/download/96860663/e42.full.pdf BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats CVMF Nascimento, C Sinezia , T Sisnande , LMTR Lima - Peptides, 2019 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S019697811930035X Development of a glucoamylase::green fluorescent protein fusion to study protein secretion in Aspergillus niger C Gordon - 2000 - search.proquest.comhttps://search.proquest.com/openview/8eb9a16060bd9e0b9556f43e2631fa62/1?pq-origsite=gscholar&cbl=2026366&diss=y Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp (a) levels , Scientific Board of GLAR for the German - Clinical research in , 2019 - Springerhttps://link.springer.com/article/10.1007/s11789-019-00094-4

• Marque: Biosynth